학술논문
Frequency of New or Enlarging Lesions on MRI Outside of Clinical Attacks in Patients With MOG-Antibody–Associated Disease
Document Type
Academic Journal
Author
B Syc-Mazurek, Stephanie; Chen, John J; Morris, Pearse; Sechi, Elia; Mandrekar, Jaywant; Tillema, Jan-Mendelt; Lopez-Chiriboga, A. Sebastian; Lucchinetti, Claudia Francesca; Zalewski, Nicholas; Cacciaguerra, Laura; Buciuc, Marina; Krecke, Karl N.; Messina, Steven Anthony; Bhatti, M. Tariq; Pittock, Sean J.; Flanagan, Eoin P.
Source
Neurology. Sep 29, 2022
Subject
Language
English
ISSN
0028-3878
Abstract
OBJECTIVE:: To determine the frequency of new or enlarging T2-hyperintense or enhancing lesions outside of clinical attacks in myelin-oligodendrocyte-glycoprotein-antibody-associated-disease (MOGAD) versus multiple sclerosis (MS) and aquaporin-4 antibody-positive-neuromyelitis-optica-spectrum-disorder (AQP4+NMOSD).Design/Methods: We retrospectively included Mayo Clinic MOGAD patients with: 1) MOG-IgG positivity by live-cell-based-assay; 2) Fulfilling proposed MOGAD diagnostic criteria; 3) Baseline and follow-up paired MRIs without interval attacks. A neurologist and neuroradiologist reviewed MRIs (T2-FLAIR brain, T2 spine, and T1-post-gadolinium brain and spine) to identify new or enlarging lesions. A MOGAD subset was then compared to MS and AQP4+NMOSD patients, based on broadly similar inter-scan intervals. RESULTS:: We included 105 MOGAD patients (median age, 31 years[range, 2-80]; 60% female) with 373 paired MRIs. In total, 10/105 (9.5%) patients and 13/373 (3%) scans had one or more new T2-lesions (brain, 12/213[6%]; spine, 1/160[0.6%]) and 8/367 (2%) had enhancing lesions. New brain lesions were less in MOGAD (1/25[4%]) than MS (14/26[54%], p<0.0001) but did not differ from AQP4+NMOSD (1/13[8%], p=1.0) in subgroup analysis. New spinal lesions were rare across groups (0-4%). CONCLUSIONS:: New or enlarging MRI lesions rarely develop outside of clinical attacks in MOGAD differing from MS. Surveillance MRIs in MOGAD have limited utility with implications for clinical practice and trial design.